Karen Bjerg Pedersen

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

Self, W. H., Sandkovsky, U., Reilly, C. S., Vock, D. M., Gottlieb, R. L., Mack, M., Golden, K., Dishner, E., Vekstein, A., Ko, E. R., Der, T., Franzone, J., Almasri, E., Fayed, M., Filbin, M. R., Hibbert, K. A., Rice, T. W., Casey, J. D., Hayanga, J. A., Badhwar, V. & 31 flere, Leshnower, B. G., Sharifpour, M., Knowlton, K. U., Peltan, I. D., Bakowska, E., Kowalska, J., Bowdish, M. E., Sturek, J. M., Rogers, A. J., Files, D. C., Mosier, J. M., Gong, M. N., Douin, D. J., Hite, R. D., Trautner, B. W., Jain, M. K., Jensen , Jens-Ulrik Stæhr , Clausen, C. L., Hovmand, N., Pedersen, Karen Bjerg, Thorlacius-Ussing, L., Tinggaard, M., Rastoder, E., Helleberg, Marie, Gerstoft, Jan, Lindegaard, Birgitte, Pedersen, T. I., Johnsen, Stine, Wiese, L., Knudsen, Lene Surland & ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, A. F. I. W. C. (. S. G., 2022, I: The Lancet Infectious Diseases. 22, 5, s. 622-635 14 s.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt